To address this clinically relevant question, we examined and demonstrated either hypoxia exposure or treatment with FG‐4592, an oral HIF‐prolyl hydroxylase (PHD) inhibitor, significantly accelerated the recovery from various forms of hepcidin‐activated anemias. Here, PDC is linked to anemia (phenotype).